TSLA
Tesla
-- 236.260 NVDA
NVIDIA
-- 118.530 PLTR
Palantir
-- 87.390 MU
Micron Technology
-- 103.000 INTC
Intel
-- 23.960 
NEWS
IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting
Tuesday, 10th December at 7:00 am
• INB-100 continues to demonstrate durable complete remissions (CR) with no relapses observed in any acute myeloid leukemia (AML) patients including those with high-risk disease after a median follow-up of 19.7 months.
• Data highlights INB-100's long-term impact, exhibiting durable in vivo expansion and persistence of allogeneic gamma-delta T cells 365 days following a single administration of INB-100, demonstrating the first-ever durable persistence and expansion of an allogeneic cellular therapy.
• New clinical data, including results from the INB-100 expansion cohort and control data, expected to be available in the first half of 2025.
Tuesday, 10th December at 7:00 am
• INB-100 continues to demonstrate durable complete remissions (CR) with no relapses observed in any acute myeloid leukemia (AML) patients including those with high-risk disease after a median follow-up of 19.7 months.
• Data highlights INB-100's long-term impact, exhibiting durable in vivo expansion and persistence of allogeneic gamma-delta T cells 365 days following a single administration of INB-100, demonstrating the first-ever durable persistence and expansion of an allogeneic cellular therapy.
• New clinical data, including results from the INB-100 expansion cohort and control data, expected to be available in the first half of 2025.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment